Lijun Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lijun Liu has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Kevin P. Battaile
New York Structural Biology Center
54 shared publications - Scott Lovell
Protein Structure and X-ray Crystallography Laboratory, University of Kansas, Lawrence, KS 66047, USA
53 shared publications - Alexandra Indeglia
University of Pennsylvania 3 Graduate Group in Biochemistry and Molecular Biophysics, Perelman School of Medicine Philadelphia, Pennsylvania
50 shared publications - Andrew V. Kossenkov
The Wistar Institute, Philadelphia, Pennsylvania
50 shared publications - Chunlei Shao
Program in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania
50 shared publications - Cindy Lin
Program in Immunology, Microenvironment and Metastasis, The Wistar Institute, Philadelphia, Pennsylvania
50 shared publications
Latest Publications
- Open Access
- 4 May 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (5) , e1072-e1082
Structure-Guided Design of Calcium-Dependent Protein Kinase 1 Inhibitors for Cryptosporidiosis
Background: Calcium-dependent protein kinase 1 (CDPK1) has emerged as a protozoan-specific target for the treatment of cryptosporidiosis. A previous study identified pyridopyrimidinones as new Cryptosporidium parvum CDPK1 (CpCDPK1) inhibitors with potent growth inhibition against C. parvum and Cryptosporidium hominis. Docking analyses suggested the unique positioning of the kinase's αC-helix could present refinement opportunities. Methods: Compounds designed to optimize the pyridopyrimidinones focused on the back-pocket region predicted to be proximal to the αC-helix, the solvent-exposed region, and the ATP ribose-binding site. Designed derivatives were synthesized and assessed for CpCDPK1 and Src kinase inhibition and for Cryptosporidium spp growth inhibition in mammalian cells. AMP/Mg+2 and 3 inhibitors were cocrystalized with CpCDPK1, and 2 inhibitors were profiled for kinase selectivity. Results: WIN 4-88 was identified with CpCDPK1 (half maximum inhibitory concentration [IC50] = 0.056 μM), and growth inhibition of zoonotic C. parvum NLuc (half maximum effective concentration [EC50] = 0.042 μM), anthroponotic C. parvum Tu114 (EC50 = 0.030 μM), and C. hominis Tu502 (EC50 = 0.062 μM), as well as enhanced kinome selectivity. The crystal structures confirmed the predicted binding mode, indicating key interactions with hinge residue Y155, similar orientations of the solvent-expose moieties, occupancy of the back pocket near the αC-helix, and for 1 inhibitor containing a solubilizing hydroxyethyl attached to the central heterocycle extension into the ATP ribose-binding site. Conclusions: The expanded structure-activity relationship and structural insights will potentially be applicable to other chemotypes with similar binding modes and will enhance development of CpCDPK1 inhibitors for the treatment of cryptosporidiosis.
- 4 May 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (5) , e1072-e1082
Open AccessStructure-Guided Design of Calcium-Dependent Protein Kinase 1 Inhibitors for Cryptosporidiosis
Background: Calcium-dependent protein kinase 1 (CDPK1) has emerged as a protozoan-specific target for the treatment of cryptosporidiosis. A previous study identified pyridopyrimidinones as new Cryptosporidium parvum CDPK1 (CpCDPK1) inhibitors with potent growth inhibition against C. parvum and Cryptosporidium hominis. Docking analyses suggested the unique positioning of the kinase's αC-helix could present refinement opportunities. Methods: Compounds designed to optimize the pyridopyrimidinones focused on the back-pocket region predicted to be proximal to the αC-helix, the solvent-exposed region, and the ATP ribose-binding site. Designed derivatives were synthesized and assessed for CpCDPK1 and Src kinase inhibition and for Cryptosporidium spp growth inhibition in mammalian cells. AMP/Mg+2 and 3 inhibitors were cocrystalized with CpCDPK1, and 2 inhibitors were profiled for kinase selectivity. Results: WIN 4-88 was identified with CpCDPK1 (half maximum inhibitory concentration [IC50] = 0.056 μM), and growth inhibition of zoonotic C. parvum NLuc (half maximum effective concentration [EC50] = 0.042 μM), anthroponotic C. parvum Tu114 (EC50 = 0.030 μM), and C. hominis Tu502 (EC50 = 0.062 μM), as well as enhanced kinome selectivity. The crystal structures confirmed the predicted binding mode, indicating key interactions with hinge residue Y155, similar orientations of the solvent-expose moieties, occupancy of the back pocket near the αC-helix, and for 1 inhibitor containing a solubilizing hydroxyethyl attached to the central heterocycle extension into the ATP ribose-binding site. Conclusions: The expanded structure-activity relationship and structural insights will potentially be applicable to other chemotypes with similar binding modes and will enhance development of CpCDPK1 inhibitors for the treatment of cryptosporidiosis.
- Open Access
Trichomonas vaginalis PPi-dependent phosphofructokinase structures reveal a non-canonical nucleotide binding site
Pyrophosphate-dependent phosphofructokinases provide an alternative route through central carbon metabolism by using inorganic pyrophosphate rather than ATP to phosphorylate fructose-6-phosphate. These enzymes are absent from mammals but occur in several anaerobic and parasitic organisms, where they may support metabolic flexibility and represent potential therapeutic vulnerabilities. Here, we report three crystal structures of Trichomonas vaginalis PPi-dependent phosphofructokinase 1 (TvPPi-PFK), a cytosolic enzyme that contributes substantially to parasite glycolytic flux. The structures show that TvPPi-PFK adopts the conserved two-domain PFK fold, assembles as a tetramer, and preserves the canonical PPi/MgPPi²⁻-binding motifs required for pyrophosphate-dependent catalysis. Mass photometry confirms that TvPPi-PFK is predominantly tetrameric in solution and shows that nucleotide- and Mg²⁺/PPi-containing conditions further stabilize the tetrameric assembly. Unexpectedly, the ligand-bound structures reveal ATP, AMP, and sugar-phosphate ligands at a recurring dimer-interface site that is spatially distinct from the canonical PPi/MgPPi²⁻ catalytic donor-binding pocket. This non-canonical interface is more accessible in TvPPi-PFK than in available PPi-PFK structures, suggesting a previously unrecognized ligand-recognition feature. These findings expand the structural landscape of the PFK superfamily and provide a framework for testing how nucleotide and sugar-phosphate binding may influence TvPPi-PFK function, regulation, and future antitrichomonal drug-discovery efforts.
Open AccessTrichomonas vaginalis PPi-dependent phosphofructokinase structures reveal a non-canonical nucleotide binding site
Pyrophosphate-dependent phosphofructokinases provide an alternative route through central carbon metabolism by using inorganic pyrophosphate rather than ATP to phosphorylate fructose-6-phosphate. These enzymes are absent from mammals but occur in several anaerobic and parasitic organisms, where they may support metabolic flexibility and represent potential therapeutic vulnerabilities. Here, we report three crystal structures of Trichomonas vaginalis PPi-dependent phosphofructokinase 1 (TvPPi-PFK), a cytosolic enzyme that contributes substantially to parasite glycolytic flux. The structures show that TvPPi-PFK adopts the conserved two-domain PFK fold, assembles as a tetramer, and preserves the canonical PPi/MgPPi²⁻-binding motifs required for pyrophosphate-dependent catalysis. Mass photometry confirms that TvPPi-PFK is predominantly tetrameric in solution and shows that nucleotide- and Mg²⁺/PPi-containing conditions further stabilize the tetrameric assembly. Unexpectedly, the ligand-bound structures reveal ATP, AMP, and sugar-phosphate ligands at a recurring dimer-interface site that is spatially distinct from the canonical PPi/MgPPi²⁻ catalytic donor-binding pocket. This non-canonical interface is more accessible in TvPPi-PFK than in available PPi-PFK structures, suggesting a previously unrecognized ligand-recognition feature. These findings expand the structural landscape of the PFK superfamily and provide a framework for testing how nucleotide and sugar-phosphate binding may influence TvPPi-PFK function, regulation, and future antitrichomonal drug-discovery efforts.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Evaluating the association between AA, Y107H variant, and cancer risk.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Evaluating the association between AA, Y107H variant, and cancer risk.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Extra crystallographic data for p53Y107H.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Extra crystallographic data for p53Y107H.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Key Reagents List for this study.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Key Reagents List for this study.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Secondary Validations of top drug hits from HCT116 WT vs Y107H clones.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Secondary Validations of top drug hits from HCT116 WT vs Y107H clones.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S8 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Supplementary Figure S1. The Y107H variant of p53 is comparable to WT p53 for growth suppression and apoptosis. Supplementary Figure S2. The Y107H variant is impaired for transactivation of a subset of p53 target genes, including PADI4, PLTP, and HHAT. Supplementary Figure S3. The Y107H protein is impaired for binding to p53 response elements. Supplementary Figure S4. Structural analysis of the Y107H variant shows similar structure but decreased thermal stability and increased propensity to misfold into mutant p53 conformation. Supplementary Figure S5. Mice with the Y107H variant have increased cancer risk. Supplementary Figure S6. Colorectal cancer cells harboring hypomorphic variants have increased sensitivity to the glutaminase inhibitor CB-839. Supplementary Figure S7. PADI4 is a p53 target and has tumor suppressive activity. Supplementary Figure S8. PADI4 correlates with increased immune signatures and wild-type p53 in human cancers.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S8 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Supplementary Figure S1. The Y107H variant of p53 is comparable to WT p53 for growth suppression and apoptosis. Supplementary Figure S2. The Y107H variant is impaired for transactivation of a subset of p53 target genes, including PADI4, PLTP, and HHAT. Supplementary Figure S3. The Y107H protein is impaired for binding to p53 response elements. Supplementary Figure S4. Structural analysis of the Y107H variant shows similar structure but decreased thermal stability and increased propensity to misfold into mutant p53 conformation. Supplementary Figure S5. Mice with the Y107H variant have increased cancer risk. Supplementary Figure S6. Colorectal cancer cells harboring hypomorphic variants have increased sensitivity to the glutaminase inhibitor CB-839. Supplementary Figure S7. PADI4 is a p53 target and has tumor suppressive activity. Supplementary Figure S8. PADI4 correlates with increased immune signatures and wild-type p53 in human cancers.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Oligos for ChIP-qPCR and qPCR used in this study
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
Oligos for ChIP-qPCR and qPCR used in this study
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
RNA-seq of top genes identified in Y107H vs WT LCLs, related to Figure 2.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression
RNA-seq of top genes identified in Y107H vs WT LCLs, related to Figure 2.